FDAsafety guidance72% confidence
Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Pharmaceutical companies focusing on mental health.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neuroscience · Alcohol Use Disorder
- Sub-indication
- General
Related signal: Study on Alcohol's Impact on PDE4B Imaging in Healthy Adults